The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.
September 12, 2019 – Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American Society for Radiation Oncology (ASTRO) 2019 annual meeting, Sept. 15-18 in Chicago. The company says its biology-guided radiotherapy (BgRT) platform is the first and only technology that unlocks the biological signature of each tumor to characterize its movement and direct highly conformal treatment to the tumor.
RefleXion also announced it will host a series of events with industry thought leaders highlighting combination therapies for metastatic disease.
“Evidence is weak for clinically relevant systemic effects of single-lesion radiation in metastatic cancer, however recent studies suggest that immunotherapy may augment the local effects of radiotherapy,” said Jason Luke, M.D., director of the Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center and associate professor of medicine at the University of Pittsburgh School of Medicine.
“Prior studies have used conventional stereotactic radiotherapy approaches generally treating one or two tumors,” continued Luke. “The potential for BgRT to treat more sites of disease may facilitate a massive reduction in tumor burden and potentially augment systemic immune activation. For the oncology community, exploring the combination of BgRT with cancer immunotherapy is of high interest to improve outcomes for patients.”
RefleXion’s approach offers a significant change in strategy from single-tumor therapy to the ability to one day treat multiple targets in the same treatment session in cancers that have metastasized. The technology incorporates a well-established modality for cancer staging and imaging, positron emission tomography (PET), which enables tumors to continuously signal their location. Using the anatomic data from computed tomography (CT) and the PET imaging data, the RefleXion machine detects PET emissions and immediately sends beamlets of radiation directly to the tumor to destroy it. The RefleXion machine also improves upon the delivery of conventional radiotherapy for single-site cancers.
The RefleXion Machine requires U.S. Food and Drug Administration (FDA) 510(k) clearance and is not yet commercially available in the United States.
For more information: www.reflexion.com